Key result
Administration of either rosuvastatin or all-trans retinoic acid ameliorated cardiac remodeling and improved all studied parameters in male albino rats.
Why the study?
Does rosuvastatin or all-trans retinoic acid ameliorate cardiac remodeling in a rat model of L-NAME-induced hypertension?
Does rosuvastatin or all-trans retinoic acid ameliorate cardiac remodeling in a rat model of L-NAME-induced hypertension?
Targeting p38MAPK with rosuvastatin or all-trans retinoic acid ameliorates cardiac remodeling in a rat model of nitric oxide inhibition.
May support p38MAPK targeting in hypertensive remodeling; hypothesis-generating in rats, should not yet change practice.
BACKGROUND: Increasing evidence suggests that the activation of p38 mitogen-activated protein kinase (p38MAPK) plays a role in cardiac remodeling. Targeting p38MAPK using drugs reported to interfere with its phosphorylation, namely statins and all-trans retinoic acid (atRA), might play a role in ameliorating this remodeling. METHODS AND RESULTS: Cardiac remodeling was induced in male albino rats by chronic inhibition of nitric oxide (NO) synthesis by N-nitro L-arginine methyl ester (L-NAME). Daily oral administration of L-NAME for 4 weeks resulted in the elevation of mean arterial blood pressure (MABP) together with cardiac remodeling evidenced by an increase in left ventricular-body weight ratio together with an increase in cardiac hydroxyproline concentration and a decrease in left ventricular papillary muscle-developed tension. An elevation in cardiac phosphorylated p38MAPK concentration, tumor necrosis factor alpha concentration and in cardiac caspase 3 activity was also observed. Administration of either rosuvastatin or all-trans retinoic acid (atRA), starting 4 weeks after L-NAME administration, ameliorated remodeling and improved all studied parameters. CONCLUSIONS: Targeting MAPK might represent a useful therapeutic avenue to ameliorate cardiac remodeling and support the notion that atRA and statins are potential candidates for the prevention and therapy of cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Baraka et al. (2009) studied Cardiac remodeling. Rosuvastatin or all-trans retinoic acid (atRA) vs. Control (L-NAME only) was evaluated on Cardiac remodeling parameters (left ventricular-body weight ratio, cardiac hydroxyproline, papillary muscle tension, p38MAPK, TNF-alpha, caspase 3). Administration of either rosuvastatin or all-trans retinoic acid ameliorated cardiac remodeling and improved all studied parameters in male albino rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: